Longboard Pharmaceuticals Inc (NASDAQ:LBPH)’s traded shares stood at 0.31 million during the last session, with the company’s beta value hitting 1.26. At the close of trading, the stock’s price was $34.79, to imply a decrease of -0.85% or -$0.3 in intraday trading. The LBPH share’s 52-week high remains $40.48, putting it -16.36% down since that peak but still an impressive 89.65% since price per share fell to its 52-week low of $3.60. The company has a valuation of $1.35B, with an average of 0.38 million shares in intraday trading volume over the past 10 days and average of 588.46K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Longboard Pharmaceuticals Inc (LBPH), translating to a mean rating of 1.14. Of 4 analyst(s) looking at the stock, 0 analyst(s) give LBPH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.56.

Longboard Pharmaceuticals Inc (NASDAQ:LBPH) trade information

After registering a -0.85% downside in the last session, Longboard Pharmaceuticals Inc (LBPH) has traded red over the past five days. The 5-day price performance for the stock is 0.35%, and -2.88% over 30 days. With these gigs, the year-to-date price performance is 476.95%. Short interest in Longboard Pharmaceuticals Inc (NASDAQ:LBPH) saw shorts transact 4.96 million shares and set a 6.06 days time to cover.

The extremes give us $16 and $90 for target low and target high price respectively. As such, LBPH has been trading -158.7% off suggested target high and 54.01% from its likely low.

Longboard Pharmaceuticals Inc (LBPH) estimates and forecasts

Looking at statistics comparing Longboard Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Longboard Pharmaceuticals Inc (LBPH) shares are 54.83% up over the last 6 months, with its year-to-date growth rate lower than industry average at 14.23% against 18.60%.

Revenue forecast for the current quarter as set by 5.0 analysts is nan. Meanwhile, for the current quarter, a total of 5.0 analyst(s) estimate revenue growth to nan.Earnings reports from the last fiscal year show that sales brought in nan and nan respectively in the corresponding quarters.

LBPH Dividends

Longboard Pharmaceuticals Inc has its next earnings report out on 2024-Oct-31. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Longboard Pharmaceuticals Inc (NASDAQ:LBPH)’s Major holders

Longboard Pharmaceuticals Inc insiders hold 1.31% of total outstanding shares, with institutional holders owning 117.73% of the shares at 119.29% float percentage. In total, 117.73% institutions holds shares in the company, led by FMR LLC. As of 2024-06-30, the company held over 4.42 million shares (or 11.3559% of shares), all amounting to roughly $119.34 million.

The next major institution holding the largest number of shares is RA CAPITAL MANAGEMENT, L.P. with 3.29 million shares, or about 8.4596% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $88.9 million.

We also have Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Longboard Pharmaceuticals Inc (LBPH) shares. Going by data provided on Jun 30, 2024 , Fidelity Select Portfolios – Biotechnology holds roughly 1.78 shares. This is just over 5.19% of the total shares, with a market valuation of $61.87 million. Data from the same date shows that the other fund manager holds a little less at 1.09, or 3.19% of the shares, all valued at about 38.07 million.